{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:37:07Z","timestamp":1740116227009,"version":"3.37.3"},"reference-count":25,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1645,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1177\/0091270010369240","type":"journal-article","created":{"date-parts":[[2010,5,20]],"date-time":"2010-05-20T02:44:42Z","timestamp":1274323482000},"page":"406-412","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetics of Laropiprant, a Selective Prostaglandin D<sub>2<\/sub>Receptor 1 Antagonist, in Patients With Moderate Hepatic Impairment"],"prefix":"10.1002","volume":"51","author":[{"given":"Ying-Hong","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie Ann Mabalot","family":"Luk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Nirula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy O.","family":"Johnson-Levonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Lasseter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Marbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. Martin","family":"Lunde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eseng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"10.1177\/0091270010369240-BIB1|cit1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2796.2005.01528.x","article-title":"Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review","volume":"258","author":"Carlson","year":"2005","journal-title":"J Intern Med"},{"key":"10.1177\/0091270010369240-BIB2|cit2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11883-000-0096-y","article-title":"Niacin dosing: relationship to benefits and adverse effects","volume":"2","author":"Capuzzi","year":"2000","journal-title":"Curr Atheroscler Rep"},{"key":"10.1177\/0091270010369240-BIB3|cit3","first-page":"229","article-title":"Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice","volume":"62","author":"Birjmohun","year":"2004","journal-title":"Neth J Med"},{"key":"10.1177\/0091270010369240-BIB4|cit4","doi-asserted-by":"crossref","first-page":"29U","DOI":"10.1016\/S0002-9149(98)00732-2","article-title":"A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients","volume":"82","author":"Morgan","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1177\/0091270010369240-BIB5|cit5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1472-6904-3-4","article-title":"The safety of over-the-counter niacin: a randomized placebo-controlled trial [ISRCTN-18054903]","volume":"3","author":"Mills","year":"2003","journal-title":"BMC Clin Pharmacol"},{"key":"10.1177\/0091270010369240-BIB6|cit6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0090-6980(89)90088-9","article-title":"Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid","volume":"38","author":"Morrow","year":"1989","journal-title":"Prostaglandins"},{"key":"10.1177\/0091270010369240-BIB7|cit7","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/1523-1747.ep12499963","article-title":"Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans","volume":"98","author":"Morrow","year":"1992","journal-title":"J Invest Dermatol"},{"key":"10.1177\/0091270010369240-BIB8|cit8","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(81)92627-1","article-title":"Is cutaneous flushing prostaglandin mediated","volume":"1","author":"Phillips","year":"1981","journal-title":"Lancet"},{"key":"10.1177\/0091270010369240-BIB9|cit9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/clpt.1985.170","article-title":"Prostaglandins and nicotinate-provoked increase in cutaneous blood flow","volume":"38","author":"Wilkin","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"10.1177\/0091270010369240-BIB10|cit10","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1038\/sj.jid.5700586","article-title":"Langerhans cells release prostaglandin D2 in response to nicotinic acid","volume":"126","author":"Maciejewski-Lenoir","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1177\/0091270010369240-BIB11|cit11","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.0601574103","article-title":"Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans","volume":"103","author":"Cheng","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1177\/0091270010369240-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1124\/mol.106.030833","article-title":"Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells","volume":"70","author":"Benyo","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1177\/0091270010369240-BIB13|cit13","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1080\/00498250601175565","article-title":"The pharmacokinetics and disposition of MK-0524, a prosglandin D2 receptor 1 antagonist, in rats, dogs and monkeys","volume":"37","author":"Chang","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1177\/0091270010369240-BIB14|cit14","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/sj.clpt.6100180","article-title":"Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D-2 receptor subtype 1","volume":"81","author":"Lai","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1177\/0091270010369240-BIB15|cit15","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1016\/j.bmcl.2007.03.058","article-title":"Metabolic activation of indole-containing prostaglandin D2 receptor 1 antagonists: impacts of glutathione trapping and glucuronide conjugation on covalent binding","volume":"17","author":"Levesque","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1177\/0091270010369240-BIB16|cit16","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1021\/jm0603668","article-title":"Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocy clopenta[b]indol-3-yl]-acetic acid (MK-0524)","volume":"50","author":"Sturino","year":"2007","journal-title":"J Med Chem"},{"key":"10.1177\/0091270010369240-BIB17|cit17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.amjcard.2007.10.023","article-title":"Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia","volume":"101","author":"Paolini","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1177\/0091270010369240-BIB18|cit18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1124\/dmd.106.011551","article-title":"Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans","volume":"35","author":"Dean","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1177\/0091270010369240-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1124\/dmd.107.014696","article-title":"Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans","volume":"35","author":"Karanam","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1177\/0091270010369240-BIB20|cit20","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/ajhp\/60.10.995","article-title":"Niacin for dyslipidemia: considerations in product selection","volume":"60","author":"McKenney","year":"2003","journal-title":"Am J Health Syst Pharm"},{"key":"10.1177\/0091270010369240-BIB21|cit21","first-page":"S308","article-title":"Understanding niacin formulations","volume":"8","author":"Pieper","year":"2002","journal-title":"Am J Manag Care"},{"key":"10.1177\/0091270010369240-BIB22|cit22","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg"},{"key":"10.1177\/0091270010369240-BIB23|cit23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jchromb.2006.04.022","article-title":"Determination of a prostaglandin D2 antagonist and its acyl glucuronide metabolite in human plasma by high performance liquid chromatography with tandem mass spectrometric detection: a lack of MS\/MS selectivity between a glucuronide conjugate and a phase I metabolite","volume":"837","author":"Schwartz","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1177\/0091270010369240-BIB24|cit24","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/sj.clpt.6100345","article-title":"Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist","volume":"83","author":"Lai","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1177\/0091270010369240-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0022-3565(24)38249-7","article-title":"Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers","volume":"289","author":"Furlan","year":"1999","journal-title":"J Pharmacol Exp Ther"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270010369240","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1177\/0091270010369240","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:16:08Z","timestamp":1740096968000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1177\/0091270010369240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"URL":"https:\/\/doi.org\/10.1177\/0091270010369240","relation":{},"ISSN":["0091-2700"],"issn-type":[{"type":"print","value":"0091-2700"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}